Last reviewed · How we verify
Coumadin
At a glance
| Generic name | Coumadin |
|---|---|
| Also known as | Odiparcil, Warfarin, warfarin, Warfarin sodium |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- SWITCH: Apixaban vs Vitamin K in HM3 (PHASE3)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- Personalized Medicine Decision-Making in a Virtual Clinical Setting
- The PEERLESS II Study (NA)
- Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation (NA)
- LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coumadin CI brief — competitive landscape report
- Coumadin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI